2023. Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s141. DOI:https://doi.org/10.25251/skin.7.supp.141.